Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc)

被引：0
|
作者：
Powles, T. [1 ]
Motzer, R. J. [2 ]
George, D. J. [3 ]
Jonasch, E. [4 ]
Pal, S. [5 ]
Tannir, N. M. [4 ]
Signoretti, S. [6 ]
Mai, T. H. [7 ]
Scheffold, C. [8 ]
Wang, E. [9 ]
Aftab, D. T. [10 ]
Escudier, B. [11 ]
Choueiri, T. K. [12 ]
机构：
[1] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England
[2] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA
[3] Duke Univ Med Ctr, Duke Canc Inst, Durham, NC USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[5] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA
[6] Brigham & Womens Hosp, Pathol, 75 Francis St, Boston, MA 02115 USA
[7] Ann Arbor Pharmacometr Grp, Pharmacometr, Ann Arbor, MI USA
[8] Exelixis Inc, Clin Dev, San Francisco, CA USA
[9] Exelixis Inc, Translat Med, San Francisco, CA USA
[10] Exelixis Inc, Execut Adm, San Francisco, CA USA
[11] Gustave Roussy, Med Oncol, Villejuif, France
[12] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
872P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)
    Rimassa, L.
    Kelley, R. K.
    Meyer, T.
    Ryoo, B-Y.
    Merle, P.
    Park, J-W.
    Blanc, J-F.
    Lim, H. Y.
    Tran, A.
    Borgman-Hagey, A. E.
    Clary, D. O.
    Wang, E.
    Cheng, A-L.
    El-Khoueiry, A. B.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2019, 30 : 257 - U138
  • [42] Expression of the receptor tyrosine kinase AXL and clinical outcomes to cabozantinib and everolimus in patients with metastatic renal cell carcinoma enrolled in the METEOR trial
    Laimon, Yasmin Nabil
    Paul, Morgan
    Ghandour, Fatme
    El Ahmar, Nourhan
    Matar, Sayed
    Denize, Thomas
    Sheshdeh, Aseman Bagheri
    Savla, Varunika
    Mohanna, Razan Assaad
    Sun, Maxine
    Saliby, Renee Maria
    Saad, Eddy
    Machaalani, Marc
    Braun, David A.
    Aftab, Dana T.
    Xie, Wanling
    Choueiri, Toni K.
    Signoretti, Sabina
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial
    Meric-Bernstam, Funda
    Tannir, Nizar M.
    Iliopoulos, Othon
    Lee, Richard J.
    Telli, Melinda L.
    Fan, Alice C.
    DeMichele, Angela
    Haas, Naomi B.
    Patel, Manish R.
    Harding, James J.
    Voss, Martin H.
    Owonikoko, Taofeek K.
    Carthon, Bradley
    Srinivasan, Ramaprasad
    Bendell, Johanna C.
    Jenkins, Yonchu
    Whiting, Sam H.
    Orford, Keith
    Bennett, Mark K.
    Bauer, Todd M.
    CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1540 - 1548
  • [44] Biomarkers before and after nephrectomy of locally advanced or metastatic renal cell carcinoma (RCC) treated with everolimus: Neorad phase 2 trial (PREDICT consortium)
    Oudard, S.
    Mejean, A.
    Topart, D.
    Thuret, R.
    Tournigand, C.
    Salomon, L.
    Thiery-Vuillemin, A.
    Guichard, G.
    Le Moulec, S.
    Houlgatte, A.
    Guillot, A.
    Mottet, N.
    Cessot, A.
    Barry-Delongchamps, N.
    Elaidi, R.
    Turajlic, S.
    Swanton, C.
    Escudier, B.
    Patard, J. J.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [45] Randomized phase iii trial of sorafenib in advanced renal cell carcinoma (RCC): Iimpact of crossover on survival
    Eisen, T.
    Bukowski, R.
    Staehler, M.
    Szczylik, C.
    S., Oudard
    Stadler, W.
    Simantov, R.
    Shan, M.
    Escudier, B.
    EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 237 - 237
  • [46] Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival
    Eisen, T.
    Bukowski, R. M.
    Staehler, M.
    Szczylik, C.
    Oudard, S.
    Stadler, W. M.
    Schwartz, B.
    Simantov, R.
    Shan, M.
    Escudier, B.
    ANNALS OF ONCOLOGY, 2006, 17 : 54 - 54
  • [47] Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma The CANTATA Randomized Clinical Trial
    Tannir, Nizar M.
    Agarwal, Neeraj
    Porta, Camillo
    Lawrence, Nicola J.
    Motzer, Robert
    McGregor, Bradley
    Lee, Richard J.
    Jain, Rohit K.
    Davis, Nancy
    Appleman, Leonard J.
    Goodman, Oscar, Jr.
    Stadler, Walter M.
    Gandhi, Sunil
    Geynisman, Daniel M.
    Iacovelli, Roberto
    Mellado, Begona
    Sepulveda Sanchez, Juan Manuel
    Figlin, Robert
    Powles, Thomas
    Akella, Lalith
    Orford, Keith
    Escudier, Bernard
    JAMA ONCOLOGY, 2022, 8 (10) : 1411 - 1418
  • [48] Population pharmacokinetic (PopPK) and exposure-response (ER) modeling of cabozantinib (C) in patients (pts) with renal cell carcinoma (RCC) in the phase 3 METEOR study.
    Lacy, Steven
    Hutmacher, Matthew M.
    Yang, Bei
    Motzer, Robert J.
    Escudier, Bernard J.
    Powles, Thomas
    Choueiri, Toni K.
    Miles, Dale
    Nielsen, Jace
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] AN ECONOMIC EVALUATION OF CABOZANTINIB VS. EVEROLIMUS IN THE SECOND-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA
    Hart, L. A.
    Carlson, J. J.
    VALUE IN HEALTH, 2017, 20 (05) : A111 - A111
  • [50] Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival.
    Eisen, T.
    Bukowski, R. M.
    Staehler, M.
    Szczylik, C.
    Oudard, S.
    Stadler, W. M.
    Schwartz, B.
    Simantov, R.
    Shan, M.
    Escudier, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 223S - 223S
12345